


Supplemental file 1. Treatment regimens for acute promyelocytic leukemia in Hong Kong.


1991-2021

Age 18-69 without cardiac comorbidities




1991-2021

Age ≥ 70 or with severe cardiac co-morbidities or ECOG ≥ 2




2013-2017 – APL001 study

Age 18-69 without cardiac comorbidities




2013-2017 APL001 study

Age ≥ 70 or with severe cardiac comorbidities or ECOG ≥ 2




APL002 study 2018-2021

Age ≥ 18 and presenting WBC < 10 × 10⁹/L or Age ≥ 65 regardless of WBC




Age ≥ 18 and presenting WBC ≥ 10 × 10⁹/L without cardiac comorbidities



2007-2020 ICC APL Study 01

Age < 18 years



ATRA: all-*trans*-retinoic acid; **DNR:** daunorubicin; **AraC:** cytarabine; **ATO:** arsenic trioxide; **MTX:** methotrexate; **6-MP:** 6-mercaptopurine; **IT:** intrathecal; **WBC:** white blood cell; **IDA:** idarubicin; **IDARAC:** intermediate dose cytarabine; **MZX:** mitoxantrone; **BM:** bone marrow; **PB:** peripheral blood; **MRD:** measurable residual disease; **d:** day/days; **x:** for; **+**: plus/positive